New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

In late November, Georgia beat Georgia Tech in a heart-stopping, eight-overtime classic. In one of the most exciting games of the entire colle ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study.

However, given the high demands of being a decorated cheerleader, Shaw is extremely cautious when it comes to cataplexy – a symptom of narcolepsy that can cause sudden loss of muscle control or even ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Q2 2025 Earnings Call Transcript July 29, 2025 Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations ...

The now 20-year-old was diagnosed with narcolepsy as a teen and uses her platform to inform people about her experience Despite her condition, she just won her second World Championship title ...

Alkermes (ALKS) reports strong Q2 2025 results with 14% growth, robust finances, and positive Phase II narcolepsy data.

– Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible – These Results ...